News

Eli Lilly: Don't Bet Against This Biotech Powerhouse

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Lilly’s Mounjaro Exhibits Heart Benefits In Type 2 Diabetes Landmark Trial

Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company ...

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...
FiercePharma17d

Mounjaro measures up to Trulicity in Eli Lilly cardio trial

Lilly has presented results from a phase 3 trial in which Mounjaro measures up head-to-head against the company’s GLP-1 Trulicity in reducing cardiovascular risks in patients with Type 2 ...

Lilly launches Mounjaro pen in India at $160 for starting dose, stepping up Novo rivalry

Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...
Straight Arrow News on MSN4d

Eli Lilly accused of bribing doctors to prescribe Mounjaro and other drugs

Texas Attorney General Ken Paxton filed a lawsuit against Eli Lilly, accusing the drug maker of bribing doctors to prescribe ...

New programme with Mounjaro maker to tackle obesity in pharmacies

The Government and pharmaceutical giant Eli Lilly, the creator of weight loss drug Mounjaro, are teaming up to explore and ...
PMLive6d

Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...